Roger Pomerantz, ContraFect CEO (via X-Vax)
July 14, 2022 10:47 AM EDTUpdated 11:05 AM
R&D

Up­dat­ed: Con­tra­Fect to ter­mi­nate PhI­II MR­SA an­tibi­ot­ic tri­al — stock cap­sizes

Lei Lei Wu

News Reporter

One year af­ter BAR­DA backed Con­tra­Fect’s MR­SA treat­ment, the Yonkers, NY-based biotech said Wednes­day it will stop its Phase III tri­al of the as­set ear­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times